coteauBeta Get App
AORT

AORT

Artivion
$22.86
-1.00% Oct 21 close
Health CareS&P 600 Compare
1M3M6M1Y2Y
-53%-35%-18%0%+17%Oct 2025Oct 2026Apr 2026
AORTSPY
1W
+6.2%
1M
-3.3%
3M
-9.1%
6M
-38.3%
YTD
-49.9%
1Y
-46.0%

Live chart

Loading live chart…

What they do

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system.

Healthcare · Medical Devices

For information only · Important disclosures

Grades vs sector

Momentum
4th percentile in sector
F
12-1 return: -49.7%
Percentile within its GICS sector across the S&P 1500.
Growth
64th percentile in sector
B
Revenue growth (YoY): +11.3%
Percentile within its GICS sector across the S&P 1500.
Value
23rd percentile in sector
D
Forward E/P: 3.4% · EBITDA/EV: 4.6%
Percentile within its GICS sector across the S&P 1500.
Profitability
20th percentile in sector
D
Profit margin: -0.7% · Return on equity: -0.7%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
Why is Artivion stock rallying today?
Investing.com · Oct 20
Artivion rises as Jefferies initiates at buy, sees ’attractive entry point’
Investing.com · Oct 20

Key stats

52-week range$20.10 – $47.63
Valuation and fundamentals

Valuation & fundamentals

Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
▲Piotroski F-score7/9
▼Net debt / EBITDA6.3x

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 29.9×
 –
Forward P/E
sector median 17.6×
 –
EV / EBITDA
sector median 15.8×
 –
Price / sales
sector median 3.1×
 –
Price / book
sector median 3.5×
 –
FCF yield
sector median 4.1%
 –

Quality & financial health

Gross margin
64.4%
Operating margin
4.4%
FCF margin
-1.9%
Net margin
-0.7%
Return on equity
-0.7%
Return on invested capital
1.8%
Net debt / EBITDA
6.3×
Current ratio
3.5×
Interest cover
0.9×
Cash conversion (OCF/NI)
–
Piotroski F-score 7/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✓ Gross margin improved✓ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FYRevenueNet incomeFree cash flow
2025$441.3M$9.8M$839.0K
2024$388.5M$-13.4M$11.0M
2023$354.0M$-30.7M$9.1M
2022$313.8M$-19.2M$-15.9M
2021$298.8M$-14.8M$-15.7M
2020$253.2M$-16.7M$5.0M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +12.0%.

Earnings

Next report: –
No EPS history available.

Stats refreshed – ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app

Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.

How it worksDisclaimerTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026